{"id":28740,"date":"2026-07-01T01:25:00","date_gmt":"2026-06-30T23:25:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=7b9da36ec96977cb77626b43a78dd62c"},"modified":"2026-07-01T01:25:00","modified_gmt":"2026-06-30T23:25:00","slug":"sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=28740","title":{"rendered":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta\u2019s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 30 individuals hired by Sarepta in the second quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p><\/a><\/a>

\nThe employees received in the aggregate 151,305 restricted stock units (\u201cRSUs\u201d). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee\u2019s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta\u2019s common stock.<\/p>

\nAbout Sarepta Therapeutics\n<\/i><\/strong>Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com<\/b><\/a> or follow us on LinkedIn<\/b><\/a>, X<\/b><\/a>, Instagram<\/b><\/a> and Facebook<\/b><\/a>.<\/p>

\nInternet Posting of Information\n<\/i><\/strong>We routinely post information that may be important to investors in the 'For Investors' section of our website at <\/i>www.sarepta.com<\/i><\/a>. We encourage investors and potential investors to consult our website regularly for important information about us.<\/i><\/p>

\nSource: Sarepta Therapeutics, Inc.<\/p> Contacts<\/b>

\nInvestor Contact:<\/i><\/b>Ian Estepan, 617-274-4052 iestepan@sarepta.com<\/a>Ryan Wong, 617-800-4112, rwong@sarepta.com<\/a>Tam Thornton, 617-803-3825, tthornton@sarepta.com<\/a>\nMedia Contact:<\/i><\/b>Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-28740","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/28740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28740"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/28740\/revisions"}],"predecessor-version":[{"id":28741,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/28740\/revisions\/28741"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}